+102.2%
USO vs MRNA
+945.0%
-842.9%
-32.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.1% | +13.1% | -21.2% | -7.7% |
| 7D | -12.7% | +20.6% | -33.3% | -12.2% |
| 30D | +1.0% | +27.1% | -26.2% | +1.7% |
| 3M | +25.6% | +353.4% | -327.8% | +33.3% |
| 6M | -1.5% | +446.3% | -447.7% | +8.7% |
| YTD | +110.3% | +776.2% | -665.9% | +118.6% |
| 1Y | +102.2% | +987.9% | -885.8% | +106.0% |
| All | +102.2% | +945.0% | -842.9% | +106.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling